May 31, 2025 08:00 AM EDTUpdated 5 hours ago

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

Max Gelman

Senior Editor

CHICAGO — Gilead and Merck made a strong case for combining Trodelvy and Keytruda in the first-line setting for an aggressive form of breast cancer. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

Max Gelman

Senior Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

AstraZeneca details its oral SERD 'switching' regimen as feasibility questions remain

Takeda, Protagonist unveil plenary data for potential blockbuster rare blood disease drug

As life-saving checkpoint drugs move to earlier cancers, researchers debate how best to use them

Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

In race with Merus, Bicara makes the case for two-year survival data

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer